


Our purpose is to create and deliver transformative medicines for people living with psychiatric and neurological conditions.



A Sanskrit word, *karuna* means "compassion in action."

Through deepening our understanding of these complex conditions, our goal is to develop medicines that can alleviate burdensome symptoms to help restore function to those living with serious mental illness.

**Powered by great science**  
We are utilizing our deep knowledge of drug mechanisms with the goal of discovering and developing medicines that make a **real difference** for people living with psychiatric conditions.

**Intentional innovators**  
Our culture is defined by our passion to serve those affected by mental illness. We are **purpose-driven** people who share a passion for working toward a goal bigger than ourselves.

**Compassion in action**  
We have a deep understanding of what advances are needed to improve people's lives and our **passion** is to serve those affected by psychiatric and neurological conditions.

### Deep expertise in neuroscience



### Our approach to drug discovery & development



Our extensive knowledge of how drugs work in the central nervous system, combined with our intimate understanding of the biology of muscarinic receptors, fuels our drug discovery and clinical efforts.



We also continue to advance an earlier stage pipeline of muscarinic receptor-targeted programs, as well as an artificial intelligence-based target agnostic drug discovery program, for treating psychiatric and neurological conditions.

### Advancing a pipeline with broad therapeutic potential

PRODUCT CANDIDATE	INDICATION	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
<b>KarXT</b> (xanomeline-trospium) M1-M4 muscarinic agonist	Schizophrenia Psychosis	[Progress bar]			
	Schizophrenia (adjunctive) Psychosis in adults with inadequate response to standard of care	[Progress bar]			
	Psychosis in Alzheimer's disease	[Progress bar]			
<b>KAR-2618*</b> TRPC4/5 inhibitor	Mood & anxiety disorders	[Progress bar]			
<b>KAR-201</b> Muscarinic-targeted drug candidate	Undisclosed	[Progress bar]			
<b>KAR-301</b> Muscarinic-targeted drug candidate	Undisclosed	[Progress bar]			
<b>KAR-401</b> Muscarinic-targeted drug candidate	Undisclosed	[Progress bar]			
<b>KAR-501</b> Target-agnostic drug candidate†	Undisclosed	[Progress bar]			

\*In-licensed KAR-2618 (formerly GFB-887) from assignment estate of Goldfinch Bio in January 2023; currently in planning stage  
† In collaboration with PsychoGenics

### Spotlight on KarXT

**KarXT (xanomeline-trospium)** is an oral, investigational M1/M4-preferring muscarinic agonist and the lead product candidate in our pipeline, currently being evaluated in Phase 3 clinical trials as both a monotherapy and adjunctive therapy for the treatment of schizophrenia, as well as for the treatment of psychosis in Alzheimer's disease. KarXT represents a major advancement in harnessing the potential of muscarinic receptors and, through its novel mechanism of action, could provide a new approach to treating psychiatric and neurological conditions.